ABNL-MARRO

The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes.

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
105 patients (estimated)
Sponsors
Vanderbilt-Ingram Cancer Center
Collaborators
Incyte Corporation, Theradex, Taiho Oncology, Inc.
Tags
Chemotherapy
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1799
NCT Identifier
NCT04061421

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.